Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes

Plamen Kozlovski, James Foley, Qing Shao, Valentina Lukashevich, Wolfgang Kothny

Plamen Kozlovski, Novartis Pharma AG, CH-4002 Basel, Switzerland
James Foley, Qing Shao, Valentina Lukashevich, Wolfgang Kothny, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, United States

Author contributions: Kozlovski P drafted the manuscript and was critical to conducting the trial, initial data interpretation and overall clinical interpretation; Kothny W contributed to study design, initial data interpretation and overall clinical interpretation; Lukashevich V was critical to designing and conducting the trial, data collection and initial data interpretation; Shao Q was responsible for the statistical analysis; Foley J contributed to the overall data interpretation; all authors were involved in manuscript revisions and are responsible for intellectual content.

Supported by Novartis Pharma AG
Correspondence to: Plamen Kozlovski, MD, Novartis Pharma AG, CH-4002 Basel, Switzerland. plamen.kozlovski@novartis.com
Telephone: +41-61-6964697 Fax: +41-61-3247921
Received: March 28, 2013 Revised: May 11, 2013 Accepted: June 18, 2013 Published online: August 15, 2013

Abstract

AIM: To assess the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to insulin in Asian patients with type 2 diabetes mellitus (T2DM).

METHODS: This was a post hoc analysis of a subgroup of Asian patients from a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in T2DM patients inadequately controlled by stable insulin therapy, with or without metformin. A total of 173 patients were randomized 1:1 to receive treatment with vildagliptin 50 mg bid (n = 87) or placebo (n = 86) for 24 wk. Changes in HbA1c and fasting plasma glucose (FPG), from baseline to study endpoint, were analyzed using an analysis of covariance model. Change from baseline to endpoint in body weight was summarized by treatment. Safety and tolerability of vildagliptin was also evaluated.

RESULTS: After 24 wk, the difference in adjusted mean change in HbA1c between vildagliptin and placebo was 0.82% (8.96 mmol/mol; P < 0.001) in Asian subgroup, 0.85% (9.29 mmol/mol; P < 0.001) in patients also receiving metformin, and 0.73% (7.98 mmol/mol; P < 0.001) in patients without metformin, all in favor of vildagliptin. There was no significant difference in the change in FPG between treatments. Weight was stable in both treatment groups (+0.3 kg and -0.2 kg, for vildagliptin and placebo, respectively). Overall, vildagliptin was safe and well tolerated with similarly low incidences of hypoglycemia (8.0% vs 8.1%) and no severe hypoglycemic events were experienced in either group.

CONCLUSION: In Asian patients inadequately controlled with insulin (with or without concomitant metformin), insulin-vildagliptin combination treatment significantly reduced HbA1c compared with placebo, without an increase in risk of hypoglycemia or weight gain.

© 2013 Baishideng. All rights reserved.

Key words: Asian; DPP-4 inhibitor; Hypoglycemia; Insulin; Oral antidiabetic drug; Type 2 diabetes; Vildagliptin

Core tip: In Asian patients, vildagliptin added to stable dose of insulin, with or without concomitant metformin, significantly improves glycemic control without increase in weight and hypoglycemia incidence.

Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes 2013; 4(4): 151-156 Available from: URL: http://www.wjgnet.com/1948-9358/full/v4/i4/151.htm DOI: http://dx.doi.org/10.4239/wjd.v4.i4.151
INTRODUCTION

The unfolding diabetes epidemic is projected to affect more than 550 million people worldwide by the year 2030 with approximately 60% of patients coming from Asia\(^4\). Despite available antidiabetic treatments, glycemic control in most Asian countries is unsatisfactory\(^5\). The progressive nature of type 2 diabetes requires continuous treatment intensification with a combination of antidiabetic agents having different mechanisms of action, and initiation of insulin therapy when beta cell function significantly deteriorates. However, delay in insulin initiation and intensification is a major problem across the world. In Asia, the mean HbA1c at the time of insulin intensification exceeds 9%\(^6\), with fear of hypoglycemia and concern of weight gain identified as the main barriers for early and optimal insulin use\(^7\). Therefore, antidiabetic agents that can significantly improve glycemic control without increasing the risk of hypoglycemia and weight gain when used in combination with insulin are needed. While the use of insulin in combination with oral antidiabetic drugs (OADs) is increasing in Asia\(^8\), there is little data from randomized controlled trials investigating the efficacy and safety of OAD-insulin combination in Asian patients with type 2 diabetes mellitus (T2DM).

Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), which extends the physiological effects of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) resulting in improvement of glycemic control in a glucose-sensitive manner\(^9\). In Asian patients with T2DM, vildagliptin showed significant improvements in HbA1c with low incidence of hypoglycemia when used as monotherapy\(^10\), in combination with metformin\(^11\), or in combination with a sulfonylurea\(^12\).

We recently reported that vildagliptin added to insulin therapy resulted in a robust improvement in glycemic control without increasing the risks of hypoglycemia and weight gain\(^13\). This study included about 40% patients from Asia (\(n = 173\)) allowing for a meaningful analysis of the efficacy and safety data in this population. Asian patients with T2DM could be more susceptible to hypoglycemia than Caucasians due to their lower body weight and increased sensitivity to insulin\(^13,14\) and there is a general lack of data in Asians as discussed above. We, therefore, analyzed the subgroup of Asian patients in this study to characterize the response to vildagliptin when combined with insulin in this growing patient population.

MATERIALS AND METHODS

Study design and patients

This was a post hoc analysis of a subgroup of Asian patients from a 24 wk, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Eligible patients included 89 men and 84 women aged 18-80 years with T2DM, HbA1c \(\geq 7.5\%\) (\(\geq 58.5\) mmol/mol) and \(\leq 11.0\%\) (\(\leq 96.7\) mmol/mol), and fasting plasma glucose levels (FPG) \(< 15\) mmol/L, who were being treated with stable insulin doses \(\leq 1\) U/kg per day (long-acting, intermediate-acting, or premixed, once or twice daily) with or without stable concomitant metformin treatment (\(\geq 1500\) mg or maximally tolerated dose) for at least 12 wk.

After a 2 wk screening period, patients were randomized in a 1:1 ratio to treatment with vildagliptin 50 mg bid or placebo. Randomization was stratified by metformin use and type of insulin used (long-acting vs intermediate acting/premixed). Further details of the study design were reported by Kothny et al\(^13\).

Study assessments and endpoints

HbA1c, FPG, and body weight were assessed at every visit, scheduled at 4 wk intervals. The efficacy endpoints were the change in HbA1c, FPG, and body weight from baseline to 24 wk or to the final visit. Safety assessments included monitoring and recording of treatment emergent adverse events (AEs), serious AEs (SAEs), biochemistry and hematology laboratory test results, electrocardiogram (ECG) findings, and vital signs.

Hypoglycemia was defined by symptoms suggestive of hypoglycemia and a self-monitored plasma glucose measurement \(< 3.1\) mmol/L. Severe hypoglycemia was defined as an episode that required assistance of another person or hospitalization with or without a plasma glucose measurement \(< 3.1\) mmol/L.

Statistical analysis

The changes in HbA1c from baseline to week 24 were compared between vildagliptin and placebo using an analysis of covariance with treatment, region, metformin use, and insulin type as classification variables and baseline HbA1c as covariate. This comparison was performed for the overall Asian population and for patients with/without concomitant metformin. Change in FPG was analyzed using the same model as for HbA1c. In addition, responder rates [percentage of patients achieving end-point HbA1c \(< 7.0\%\) (53.0 mmol/mol)] were compared between treatments using a chi-squared test. The efficacy analyses were performed on the full analysis set population consisting of all randomized patients who received at least one dose of the study drug and had at least one post-baseline assessment of any efficacy variable.

Efficacy data used in analyses were censored at the start of major changes in insulin background therapy. Major changes in insulin therapy were defined as changes occurring \(\geq 7\) d in any 30-d period or \(\geq 5\) d consecutively, including changes in insulin frequency and/or type and/or a \(\geq 10\%\) dose increase either as rescue medication or for any other reasons. The last observation carried forward (LOCF) method was used to handle missing data because of early discontinuation or data censoring.

Change in body weight from baseline to endpoint was summarized descriptively. The safety data (AEs, SAEs, including hypoglycemia) were summarized descriptively by treatment on all available data.

Ethical considerations

This trial was conducted in accordance with the Declara-
Between treatment difference in HbA1c of 0.82 ± 0.1% (8.96 ± 1.1 mmol/mol) was increased by 0.03 ± 0.2% (0.32 ± 2.2 mmol/mol) in patients receiving vildagliptin (n = 87) compared with placebo (n = 86). The adjusted between-treatment difference (vildagliptin 50 mg bid-placebo) of 0.85% (9.29 ± 0.87 mmol/mol) in patients receiving vildagliptin (n = 85) and HbA1c increased by 0.03 ± 0.2% (0.32 ± 2.2 mmol/mol) in patients receiving placebo (n = 84). The adjusted between-treatment difference (vildagliptin 50 mg bid-placebo) in HbA1c of 0.82 ± 0.1% (8.96 ± 1.1 mmol/mol) was statistically significant (P < 0.001) in favor of vildagliptin (Figure 1B).

Vildagliptin significantly reduced HbA1c in both patients with and without concomitant metformin therapy, with adjusted mean differences vs placebo of 0.85% (9.29 mmol/mol) and 0.73% (7.98 mmol/mol) (P < 0.001 for both groups), respectively, in favor of vildagliptin. In subgroups by ethnicity, reductions in HbA1c from baseline to week 24 endpoint (Figure 1A). After 24 wk of treatment, HbA1c had decreased by 0.8 ± 0.2% (8.74 ± 2.2 mmol/mol) in patients receiving vildagliptin (n = 85) and HbA1c increased by 0.03 ± 0.2% (0.32 ± 2.2 mmol/mol) in patients receiving placebo (n = 84). The adjusted between-treatment difference (vildagliptin 50 mg bid-placebo) in HbA1c of 0.82 ± 0.1% (8.96 ± 1.1 mmol/mol) was statistically significant (P < 0.001) in favor of vildagliptin (Figure 1B).

In a responder analysis, significantly more patients receiving vildagliptin achieved the HbA1c target of < 7.0% (Figure 1B).

### Results

#### Patient disposition and baseline characteristics

A total of 173 Asian patients (38.5% of the overall study population) were randomized: 87 patients to vildagliptin 50 mg bid and 86 patients to placebo. The demographic and baseline characteristics of the randomized patients are summarized in Table 1. The groups were well balanced for all the baseline characteristics. Most patients were from the Indian subcontinent (71%) followed by patients of Chinese ethnicity (27.7%) with a mean age of 54.5 years; just over 12% of patients were ≥ 65 years of age. Mean baseline values of HbA1c and FPG were 8.9% (73.8 mmol/mol) and 8.8 mmol/L, respectively. Mean body mass index (BMI) was 26.4 kg/m² and the majority (86%) had BMI < 30 kg/m². The mean duration of T2DM was 11.6 years. Mean duration of insulin use was 3.6 years, mean daily insulin dose at screening was 39.5 units, and pre-mixed insulin was the most frequent type of insulin used. Overall, 60.1% of patients were treated with metformin. The mean metformin dose at the time of randomization was approximately 2000 mg for both treatment groups.

#### Efficacy

In this Asian population, vildagliptin demonstrated consistent reductions in HbA1c from baseline to week 24 endpoint (Figure 1A). After 24 wk of treatment, HbA1c had decreased by 0.8 ± 0.2% (8.74 ± 2.2 mmol/mol) in patients receiving vildagliptin (n = 85) and HbA1c increased by 0.03 ± 0.2% (0.32 ± 2.2 mmol/mol) in patients receiving placebo (n = 84). The adjusted between-treatment difference (vildagliptin 50 mg bid-placebo) in HbA1c of 0.82 ± 0.1% (8.96 ± 1.1 mmol/mol) was statistically significant (P < 0.001) in favor of vildagliptin (Figure 1B).

Vildagliptin significantly reduced HbA1c in both patients with and without concomitant metformin therapy, with adjusted mean differences vs placebo of 0.85% (9.29 mmol/mol) and 0.73% (7.98 mmol/mol) (P < 0.001 for both groups), respectively, in favor of vildagliptin. In subgroups by ethnicity, reductions in HbA1c from baseline to week 24 endpoint (Figure 1A). After 24 wk of treatment, HbA1c had decreased by 0.8 ± 0.2% (8.74 ± 2.2 mmol/mol) in patients receiving vildagliptin (n = 85) and HbA1c increased by 0.03 ± 0.2% (0.32 ± 2.2 mmol/mol) in patients receiving placebo (n = 84). The adjusted between-treatment difference (vildagliptin 50 mg bid-placebo) in HbA1c of 0.82 ± 0.1% (8.96 ± 1.1 mmol/mol) was statistically significant (P < 0.001) in favor of vildagliptin (Figure 1B).

In a responder analysis, significantly more patients receiving vildagliptin achieved the HbA1c target of < 7.0% (Figure 1B).

### Table 1. Baseline patient demographic and background characteristics (Asian population)

| Characteristic                        | Vildagliptin 50 mg bid | Placebo |
|---------------------------------------|------------------------|---------|
|                                       | n = 87                 | n = 86  |
| Age, years                            | 54.0 ± 8.4             | 54.9 ± 10.5 |
| ≥ 65, n (%)                           | 8 (9.2)                | 13 (15.1) |
| Gender, female, n (%)                 | 45 (51.7)              | 39 (45.3) |
| Race, n (%)                           |                        |         |
| Indian (Indian subcontinent)          | 62 (71.3)              | 61 (70.9) |
| Chinese                               | 24 (27.6)              | 24 (27.9) |
| Other                                 | 1 (1.1)                | 1 (1.2)  |
| BMI kg/m²                              | 26.2 ± 3.0             | 26.7 ± 3.7 |
| Body weight, kg                       | 67.5 ± 9.5             | 68.8 ± 12.1 |
| HbA1c, % (mmol/mol)                   | 8.9 ± 1.0              | 9.0 ± 1.0 |
| (73.7 ± 10.9)                         | (74.8 ± 10.9)          |         |
| FPG, mmol/L                           | 9.1 ± 2.6              | 8.6 ± 2.5 |
| T2DM duration, years                  | 11.1 ± 6.4             | 12.1 ± 7.6 |
| GFR, ml/min per 1.73 m², n (%)        |                        |         |
| Normal, ≥ 80                          | 43 (49.4)              | 52 (60.5) |
| Mild, > 50 to ≤ 80                    | 42 (48.3)              | 33 (38.4) |
| Moderate, > 30 to < 50                | 2 (2.3)                | 1 (1.2)  |
| Background antidiabetic therapy       |                        |         |
| Insulin use at screening, n (%)       |                        |         |
| Intermediate-acting                   | 21 (24.1)              | 20 (23.3) |
| Long-acting                           | 14 (16.1)              | 8 (9.3)  |
| Pre-mixed                             | 52 (59.8)              | 58 (67.4) |
| Duration of insulin use, years        | 3.3 ± 2.9              | 3.9 ± 4.3 |
| Daily dose of insulin, UI             | 39.5 ± 15.8            | 39.5 ± 15.3 |
| Daily number of insulin injections    | 1.9 ± 0.4              | 1.8 ± 0.4 |
| Metformin use at screening, n (%)     |                        |         |
| Yes                                   | 52 (59.8)              | 52 (60.5) |
| No                                    | 35 (40.2)              | 34 (39.5) |

Values are mean ± SD unless indicated otherwise. BMI: Body mass index; GFR: Glomerular filtration rate; FPG: Fasting plasma glucose; HbA1c: Hemoglobin A1c; T2DM: Type 2 diabetes mellitus.
and the adjudication committee concluded that it was of liver enzyme elevation reported in one vildagliptin-reflection of rapidly improving glucose levels. Of 6.5% (47.5 mmol/mol). These events of blurred vision one had a smaller HbA1c reduction, but reached HbA1c 1.4% (15.3 mmol/mol) or more during the study; another patients experienced considerable reduction in HbA1c of 0.2 kg in the vildagliptin group and a decrease of 0.2 kg in the placebo group. Overall, the safety profile of vildagliptin in the Asian subgroup was consistent with the safety profile in the overall patient population of 0.2 kg without any clinically relevant differences between treatments.

Safety
Vildagliptin 50 mg bid added to intermediate-acting, long-acting, or premixed insulin, with or without metformin, was generally safe and well tolerated.

The overall incidence of AEs was numerically higher with vildagliptin (62.1%) than with placebo (53.5%). This difference was driven by gastrointestinal disorders (14.9% vs 7.0%), blurred vision (9.2% vs 0%), and upper respiratory tract infections (13.8% vs 8.1%). The latter were assessed by investigators as mild or moderate and not related to study drug. Diarrhea and gastritis were more frequently reported in the vildagliptin group; however, the drug was not discontinued in any of the cases.

The proportion of patients who experienced hypoglycemic events was low and similar in both treatment groups (8.0% and 8.1% in the vildagliptin and placebo groups, respectively). No patient in either treatment group experienced a severe hypoglycemic event. Similar number of patients in the vildagliptin and placebo groups reported hyperhidrosis, dizziness, tremors, and palpitations, which may be symptoms of hypoglycemia. Blurred vision was reported by 8 patients (9.2%). For three of them, blurred vision was identified as hypoglycemia and included in the hypoglycemic events summary since they had accompanying glucose measurements < 3.1 mmol/L. Of the remaining five, four reported, together with the blurred vision, one or more other symptoms suggestive of hypoglycemia (dizziness, weakness, palpitations, tremor or hyperhidrosis); however no blood glucose measurement had been performed to confirm a hypoglycemic event. Six of these eight patients experienced considerable reduction in HbA1c of 1.4% (15.3 mmol/mol) or more during the study; another one had a smaller HbA1c reduction, but reached HbA1c of 6.5% (47.5 mmol/mol). These events of blurred vision could be symptoms of hypoglycemia, or in some cases a reflection of rapidly improving glucose levels.

The rate of serious AEs was very low in this subgroup with only one serious AE reported. This was a case of liver enzyme elevation reported in one vildagliptin-treated patient with history of non-alcoholic steato-hepatitis. This event was associated with respiratory infection and the adjudication committee concluded that it was unrelated to study drug.

Body weight remained stable during the study with an increase of 0.3 kg in the vildagliptin group and a decrease of 0.2 kg in the placebo group. Overall, the safety profile of vildagliptin in the Asian subgroup was consistent with the safety profile in the overall patient population, without any clinically relevant differences between treatments.

DISCUSSION
In Asian patients, the addition of vildagliptin 50 mg bid to stable therapy with basal or pre-mixed insulin, with or without concomitant metformin, demonstrated a robust reduction in HbA1c vs placebo after 24 wk of treatment. Vildagliptin was efficacious in patients both from Indian and Chinese ethnicity with clinically relevant reductions in HbA1c from baseline of about 1.0% (10.93 mmol/mol). Importantly, the addition of vildagliptin to insulin was not associated with an increased risk for hypoglycemia or weight gain. These findings are consistent with the results from the overall study population. Mean baseline HbA1c was similar in both the overall population [8.8% (72.7 mmol/mol)] and in the Asian population [8.9% (73.8 mmol/mol)] and so was the reduction in HbA1c vs placebo after 24 wk of treatment [0.7% (7.6 mmol/mol) and 0.8% (8.7 mmol/mol), respectively].

Asian patients had lower BMI than patients in the overall study population (26.4 kg/m² vs 28.9 kg/m², respectively) which could make them more sensitive to insulin and, thus, place them at a higher risk of hypoglycemia. However, the incidence of hypoglycemia was similar for vildagliptin and placebo in spite of better glycemic control with vildagliptin indicating that vildagliptin exerts its protective effect against hypoglycemia also in Asian patients. Vildagliptin has demonstrated a protective effect against hypoglycemia at all stages of type 2 diabetes resulting from its ability to increase glucagon levels during hypoglycemia.

In this study, adding vildagliptin to a stable insulin dose was weight neutral, which is consistent with the known vildagliptin weight profile when used as monotherapy or in combination with other OADs. The weight neutrality of vildagliptin likely results in part from its intrinsically low risk for hypoglycemia and avoidance of “defensive eating” characteristic for antidiabetic agents associated with increased hypoglycemia risk. Other potential mechanisms may include possible inhibition of intestinal fat extraction and fatty acid mobilization and oxidation in the postprandial state, in conjunction with increased sympathetic stimulation.

Multinational studies with DPP-4 inhibitors added to insulin included small numbers of Asian patients and, therefore, meaningful analysis might have not been possible. However, in a Korean study, addition of sitagliptin to a stable insulin dose resulted in reduction in HbA1c of 0.6% (6.5 mmol/mol) from baseline of 9.2% (77.1 mmol/mol), with one patient experiencing severe hypoglycemia. This is consistent with the find-
DPP-4 inhibitors: Dipeptidyl peptidase-4 inhibitors are a class of oral antihyperglycemic agents that inhibit the enzyme DPP-4. They are used to treat type 2 diabetes mellitus. HbA1c: Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. It is formed in a non-enzymatic glycation pathway by hemoglobin’s exposure to plasma glucose. The 2010 American Diabetes Association Standards of Medical Care in Diabetes added the HbA1c ≥ 48 mmol/mol (≥ 6.5%) as another criterion for the diagnosis of diabetes.

### Peer review
This manuscript presents an analysis of the Asian subgroup of a recently published study. It addresses new findings regarding the effects of vildagliptin as add-on therapy in insulin in Asian patients with type 2 diabetes mellitus. The present work contains interesting data and appears timely.

### REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas, 5th edn. Brussels, Belgium. 2011. Available from: URL: http://www.idf.org/diabetesatlas

2. Bi Y, Yan JH, Liao ZH, Li YB, Zeng LY, Tang KX, Xue YM, Yang HZ, Li L, Cai DH, Wu G, Zhang F, Lin SD, Xiao ZH, Zhu DL, Weng JP. Inadequate glycemic control and anti-diabetic therapy among inpatients with type 2 diabetes in Guangdong Province of China. Chin Med J (Engl) 2008; 121: 677-681 [PMID: 18701017]

3. Chuang LM, Tsai ST, Huang BY, Tai TY. The status of diabetes control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med 2002; 19: 978-985 [PMID: 12647837 DOI: 10.1046/j.1464-5491.2002.00833.x]

4. Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, Wenying Y. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the Alchief study. Diabetes Res Clin Pract 2011; 94: 352-363 [PMID: 21553567 DOI: 10.1016/j.diabres.2011.10.021]

5. Mohamed M. An audit on diabetes management in Asian patients treated by specialists: the Diabcare-Asia 1998 and 2003 studies. Curr Med Res Opin 2008; 24: 507-514 [PMID: 18184454 DOI: 10.1185/030079908X261131]

6. Ahren B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocr Metab 2009; 94: 1226-1243 [PMID: 19174497 DOI: 10.1210/jc.2008-2152]

7. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13: 775-783 [PMID: 21507182 DOI: 10.1111/j.1463-1326.2011.01414.x]

8. Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes Obes Metab 2009; 11 Suppl 2: 9-17 [PMID: 19389079 DOI: 10.1111/j.1463-1326.2008.01033.x]

9. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 83: 233-240 [PMID: 19189153 DOI: 10.1016/j.diabres.2008.10.006]

10. Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Ly X, Lu J, Bader G. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 89: 216-223 [PMID: 20537746 DOI: 10.1016/j.diabres.2010.04.017]

11. Kohly W, Foley J, Kozlovs P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 737-744 [PMID: 22369287 DOI: 10.1111/j.1463-1326.2012.01593.x]
Kozlovski P et al. Vildagliptin-insulin combination in Asians

with type 2 diabetes mellitus. *Diabetes Obes Metab* 2013; 15: 252-257 [PMID: 2309321 DOI: 10.1111/dom.12020]

13 Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. *JAMA* 2009; 302: 2129-2140 [PMID: 19479900 DOI: 10.1001/jama.2009.726]

14 Lüddeke HJ, Sreenan S, Aczel S, Maxeiner S, Yenigun M, Kozlovski P, Gydesen H, Dornhorst A. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia. *Diabetes Obes Metab* 2007; 9: 428-434 [PMID: 17391171 DOI: 10.1111/j.1463-1326.2006.00677.x]

15 Khunti K, Srinivasan BT, Shutler S, Davies MJ. Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: data from the AT-LANTUS trial. *Diabetes Obes Metab* 2010; 12: 683-688 [PMID: 20590745 DOI: 10.1111/j.1463-1326.2010.01217.x]

16 Dejager S, Schweizer A. Minimizing the risk of hypoglycaemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. *Diabetes Ther* 2011; 2: 51-66 [PMID: 22127800 DOI: 10.1007/s13300-010-0018-0]

17 Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. *Diabetes Res Clin Pract* 2007; 76: 152-158 [PMID: 17223217 DOI: 10.1016/j.diabres.2006.12.009]

18 Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. *Diabetes Obes Metab* 2008; 10: 1114-1124 [PMID: 18355325 DOI: 10.1111/j.1463-1326.2008.00873.x]

19 Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetes Care* 2007; 30: 217-223 [PMID: 17259484 DOI: 10.2337/dc06-1815]

20 Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. *Diabetes Obes Metab* 2008; 10: 1047-1056 [PMID: 18284434 DOI: 10.1111/j.1463-1326.2008.00859.x]

21 Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. *Vasc Health Risk Manag* 2010; 6: 541-548 [PMID: 20730070 DOI: 10.2147/VHRM.S10952]

22 Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. *Curr Med Res Opin* 2012; 28: 513-523 [PMID: 22313154 DOI: 10.1185/03007995.2012.665046]

23 Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1C without causing weight gain or increased hypoglycaemia. *Diabetes Obes Metab* 2009; 11: 1145-1152 [PMID: 19758359 DOI: 10.1111/j.1463-1326.2009.01124.x]

24 Vilsbøll T, Rosenstock, J, Yki-Järvinen H, Cefalu WT, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Ama-truda JM, Engel SS, Katz L. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2010; 12: 167-177 [PMID: 20092585 DOI: 10.1111/j.1463-1326.2009.01713.x]

25 Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. *Diabetes Obes Metab* 2012; 14: 795-802 [PMID: 22434693 DOI: 10.1111/j.1463-1326.2012.01600.x]

26 Schweizer A, Foley JE, Kothny W, Ahrén B. Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin. *Vasc Health Risk Manag* 2013; 9: 57-64 [PMID: 23431062 DOI: 10.2147/VHRM.S40972]

P- Reviewers Georgescu A, Sourij H S- Editor Wen LL L- Editor A E- Editor Lu Y
